InVivo Therapeutics Corporation is a Cambridge, MA based medical device company founded to develop and commercialize groundbreaking technologies for the treatment of spinal cord injuries (SCI).
Currently, there are no treatment options for SCI patients to successfully restore function following a spinal cord injury. Existing treatments consist of a collection of approaches that only focus on symptoms of SCI, such as decompression and mechanical stabilization of the spinal cord, rather than on the underlying pathology.
InVivo intends to create a new paradigm of care by taking a novel approach to SCI. Instead of focusing exclusively on regeneration, InVivo concentrates on neuroprotection. Our products are intended to protect the spinal cord after primary injury by mitigating the bleeding, inflammation, and further cell death that result from the body’s immune response to SCI. By minimizing these secondary injury processes, and by supporting subsequent repair and recovery, the body can locally reorganize toward functional recovery through the spared healthy tissue. This process, known as neuroplasticity, may result in partial functional recovery.
InVivo has an unmatched development portfolio composed of platform technologies for the treatment of both spinal cord injury and other application. These technologies encompass multiple strategies involving biomaterials, U.S. Food & Drug Administration (FDA) approved drugs, growth factors, and human neural stem cells (hNSCs).